Novo Nordisk A/s

A/s Ferrosan

Karo Bio Ab

Nero Nordisk A/s

Poul Jacobsen

Flemming E Nielsen

Tage Honore

Paul Stanley Bury

Lise Brown Christiansen

Anders Bendtz Kanstrup

Svend Treppendahl

Jorgen Drejer

Lars Naerum

Soren Ebdrup

Per Vedso

Lone Jeppesen

Holger C Hansen

Anker S Jorgensen

Johannes Cornelis De Jong

Lars Nafrim

Jphirgen Drejer

Tage Honoree

Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

Compounds and uses thereof for decreasing activity of hormone-sensitive lipase

Use of compounds for decreasing activity of hormone-sensitive lipase

Use of compounds to inhibit hormone-sensitive lipase, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, method of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of a range of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

Pharmaceutical use of boronic acids and esters thereof

The present invention relates to therapeutically active compounds of formula I

cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.

Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or

Pyrrolo [2,1,5-cd] indolizine derivatives useful in the prevention or

cis-3,4-chroman derivatives useful in the prevention or treatment of

Trans-3,4-chroman derivatives useful in the prevention or treatment of

(+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or

The present invention relates to therapeutically active compounds of formula I a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes,

Cis-3,4-chroman derivatives useful in the prevention or treatment of

Cis-3, 4-chroman derivatives useful in the prevention or treatment of

Quinoxaline compounds of the general formula ##STR1## wherein R.sup.1 is COX', POX'X' or alkyl substituted with COX' or POX'X', and X' and X' independently are hydroxy or alkoxy, and R.sup.6, R.sup.7, R.sup.8 and R.sup.9 independently are hydrogen, alkyl, halogen, NH.sub.2, NO.sub.2, CN, CF.sub.3, SO.sub.2 NY'Y' or COZ' wherein Z' is NY'Y' or alkyl and Y' and Y' independently are hydrogen or alkyl, triazolyl, imidazolyl, imidazolyl substituted with phenyl or alkyl, or R.sup.6 and R.sup.7, or R.sup.8 and R.sup.9, together form a further fused ring, are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.

Heterocyclic compounds, their use and preparation

The present invention relates to [1,2,4]triazolo[4,3-a quinoxaline derivatives of formula I ##STR1## wherein one of R.sup.1 and R.sup.2 is a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted with one, two or three substituents, wherein each substituent is independently phenyl or C.sub.1-6 -alkyl, or one of R.sup.1 and R.sup.2 is a fused ring system comprising a 5- or 6-membered nitrogen-containing heterocyclic ring and a benzene, pyridine, pyrimidine or pyrazine ring, wherein the fused ring system is optionally substituted with phenyl or C.sub.1-6 -alkyl; and the other of R.sup.1 and R.sup.2 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, halogen, NO.sub.2, NH.sub.2, CN, CF.sub.3, COC.sub.1-6 -alkyl or SO.sub.2 NR'R', wherein R' and R' are independently hydrogen or C.sub.1-6 -alkyl; and X is O or S; and pharmaceutically acceptable salts thereof. The compounds have affinity for the AMPA receptors and are antagonists in connection with this type of receptors which makes them useful in the treatment of CNS ailments, especially in the treatment of any of the numerous indications caused by hyperactivity of excitatory amino acids.

[1,2,4]triazolo[4,3-a]quinoxaline compounds

Quinoxaline compounds represented by formulas I or II, ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, C.sub.1-6 -alkyl, halogen, NO.sub.2, NH.sub.2, CN, CF.sub.3, SO.sub.2 NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-6 -alkyl, or COR.sup.6 wherein R.sup.6 is C.sub.1-6 -alkyl; and R.sup.3 is hydrogen, C.sub.1-6 -alkyl or CF.sub.3, compositions thereof and methods of preparing the compounds are described. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.

Triazolo quinoxalines and their preparation and use

Heterocyclic dihydroxyquinoxaline compounds having the formula ##STR1## wherein R.sup.1 is hydroxy; and R.sup.5 and R.sup.6 together form a fused phenyl, cyclohexyl or pyridyl ring, which is optionally substituted with halogen or CN; and R.sup.7 and R.sup.8 independently are hydrogen, hydroxy, NO.sub.2, halogen, CN, CF.sub.3, C.sub.1-4 - acetyl, SO.sub.2 NHCOCO.sub.2 Et, SO.sub.2 NR'R' or SO.sub.2 R', wherein R' is hydrogen or C.sub.1-4 -alkyl; or R.sup.5 and R.sup.6 independently are hydroxy, hydrogen, NO.sub.2, halogen, CN, CF.sub.3, C.sub.1-4 -alkoxy, acetyl, SO.sub.2 NHCOCO.sub.2 Et, SO.sub.2 NR'R' or SO.sub.2 R', wherein R' is hydrogen or C.sub.1-4 -alkyl; and R.sup.7 and R.sup.8 together form a fused phenyl, cyclohexyl or pyridyl ring which is optionally substituted with halogen or CN.

Quinoxaline compounds and their preparation and use

Growing community of inventors

Slangerup, Denmark

Poul Jacobsen